Correspondence should be addressed to SM: stefanm@if-pan.krakow.pl G protein-coupled receptors (GPCRs) transduce external stimuli into the cell by G proteins via an allosteric mechanism. Agonist binding to the receptor stimulates GDP/GTP exchange within the heterotrimeric G protein complex. Whereas recent structures of GPCR-G protein complexes revealed that the H5, S1 and S2 domains of Gα are involved in binding the active receptor, earlier studies showed that a short peptide analogue derived from the C-terminus (H5) of the G protein transducin (G t ) is sufficient to stabilize rhodopsin in an active form. Here, we show that a Gα i -derived peptide of 12 amino acids binds the µ-opioid receptor (µOR) and acts as an allosteric modulator. The Gα i -derived peptide increases µOR affinity for its agonist morphine in a dose-dependent way. These results indicate that the GPCR-Gα peptide interaction observed so far for only rhodopsin can be extrapolated to µOR. In addition, we show that the C-terminal peptide of the Gα i subunit is sufficient to stabilize the active conformation of the receptor. Our approach opens the possibility to investigate the GPCR-G protein interface with peptide modification.
Introduction
G protein-coupled receptors (GPCRs) are a superfamily of approximately 800 receptors (in humans) transmitting extracellular stimuli (e.g., small molecules, peptides, lipids or light) into the cell. Due to their key regulatory roles in multiple cell types and tissues and their resulting potential for drug targeting, GPCRs have become the most frequently targeted protein class on the market. 1 On the other hand, the active GPCR signal is transduced into the cell by only 16 different G proteins. 2 Understanding the molecular basis of GPCR-G protein pairing is essential to understanding the phenomena of functional selectivity and biased signalling, where the type of ligand bound determines which signal transducers are activated by the receptor. Utilizing this knowledge can have significant therapeutic implications, as it may lead to novel drugs with reduced side effects. 3, 4 GPCR activation triggered by extracellular orthosteric agonists through a cascade of conformational changes opens the intracellular side of the receptor for interaction with the heterotrimeric G protein. Experimental evidence supports the model of ternary complex 5 formation by the receptor, agonist and signal transducer, where the latter stabilizes the active conformation of the receptor. 6 In this model, which is further supported by NMR studies, 7 the unbound receptor occupies a certain conformational space including the conformations corresponding to the active state (thus explaining the phenomenon of basal activity). Binding of the agonist to the receptor limits this conformational space but leaves some degree of flexibility that is further narrowed by G protein coupling. Recent functional studies shed light on the process of ternary complex formation. Work by DeVree et al. 8 postulates G proteindependent low-and high-agonist-affinity states of the receptor. Binding of the agonist promotes the interaction between the receptor and G protein (low-affinity state). Release of GDP by the G protein enables stronger interactions with the GPCR, stabilizing its active state, allosterically affecting the orthosteric (extracellular) region of the receptor, and enhancing the affinity of the agonist (high-affinity state).
Multiple pharmacological and structural studies indicate that other binding partners, including antibodies and nanobodies, 9 mini-G proteins, 10 and peptides derived from G t 11 or arrestin-1, 12 can mimic the effect of G protein binding and thus be used for investigation of GPCR activation. Among these, synthetic peptides derived from the C-terminus of Gα (Gpeptides) offer a promising avenue for investigating GPCR activation 13 , and with peptide mutations increasing the affinity to the target receptor 14 , they open a possibility for studying G protein subtype selectivity and identification of the GPCR-G protein interaction hotspots. The crystal structures of active rhodopsin have employed a G protein-derived peptide, and this peptide binds within the intracellular crevice of rhodopsin. 11, 15 Here, our aim was to investigate whether another GPCR in addition to rhodopsin could be bound and stabilized by a peptide derived from a G protein other than G t .
Results
Target selection. To determine if small peptides derived from other G proteins might be used to study GPCRs other than rhodopsin, we began by identifying the structural and topological features of rhodopsin differentiating it from other crystallized GPCRs. As there are no clear sequence motifs corresponding to matching different G proteins, 16 we looked at the more general level -i.e., the size of the intracellular loops of the receptors. It appears that intracellular loop 3 (ICL3) of rhodopsin is significantly shorter than those of other GPCRs crystallized in the active state ( Figure 1a ). Notably, short loops are actually more common than long loops among GPCRs in general, and those with a longer ICL3 are disproportionately over-represented in the small group of GPCRs that have been crystallized ( Figure 1b ). Given that fact, it should be possible to observe G-peptide binding to a receptor with an ICL3 of similar length to that of rhodopsin. We selected µ-opioid receptor (µOR) for the study. It not only matches the requirement for ICL3 length (it contains 8 residues) but also has a number of well-studied ligands with distinct functional profiles, allowing for more comprehensive experimental studies.
In vitro studies. The binding of the G-peptide was experimentally verified in vitro. We used three compounds with different functional profiles: morphine, prototyping an unbiased ligand; 17 a G i -biased agonist PZM21; 3 and fentanyl, with a strong preference towards βarrestin recruitment. 18 Previous studies on G proteins and nanobodies demonstrated the allosteric effect of binding an intracellular agent stabilizing an active conformation, 8, [19] [20] [21] resulting in increased agonist affinity for a receptor bound by G protein or nanobodies. Here, we capitalized on the same assumption, observing the changes in the results of a radioligandbinding assay. The results of in vitro experiments showed an increase in the affinity of morphine after adding the G-peptide. The leftward shift in the binding curve and the increased amount of radioligand bound indicate the allosteric effect of the added peptide (Figure 2a, 2e ). On the other hand, the same experiment with the G protein-biased agonist PZM21 resulted in an increase in the affinity towards µOR but no change in the amount of radioligand bound (Figure 2b, 2f ). Finally, the binding affinity of fentanyl was not affected by the G-peptide, but we observed a significantly increased amount of radioligand bound (Figure 2c, 2g ). At the same time, the peptide itself did not interact directly with the orthosteric binding site. A binding experiment performed for the G-peptide allowed us to estimate the affinity of the peptide in the micromolar range, which was four orders of magnitude lower than those measured for the reference ligands ( Supplementary Figure 1) . Saturation experiments performed for [H 3 ]DAMGO confirmed the dose dependency of the affinity increase caused by the G-peptide, providing additional confirmation that the allosteric effects we observed in the binding studies are indeed caused by the peptide (Supplementary Figure 2 ).
Computational study. In complement to the in vitro experiments, we studied the interactions between the G-peptide and µOR in silico to gain insight into the formation of the ternary complex. µOR has been crystallized in both active (PDB 22 code: 5C1M 20 ) and inactive (PDB code: 4DKL 23 ) conformations and, recently, in complex with G i (PDB code: 6DDE 24 ). Unlike previous computational studies on GPCR-G protein complexes, 25, 26 where the starting point of the simulations was inferred from the crystal structure of the β 2 -AR-G s complex, 27 we performed simulations of the systems containing the receptor with docked morphine along with one G-peptide in close proximity to the intracellular binding site. The purpose of the simulations was to evaluate whether the peptide is likely to enter the crevice of µOR and whether it forms stable complexes with the receptor. We also performed simulations of the Gpeptide in water, showing the oscillations between the helical and unstructured states ( Supplementary Figure 4 ). For simulations with an inactive-state receptor, we observed the peptide approaching the binding site and making a network of contacts with µOR, with a number of hydrogen bonds between R 3x50 and G.H5.22 (denoted in common numbering schemes for GPCRs 28 and G proteins, 16 respectively) as the main contributors ( Figure 3c ). A comparison of the conformation of the complex and recently released µOR-G i complex revealed a similar angle of H5; however, the simulated G-peptide was translated by one helix turn due to the closed intracellular binding cleft (Figure 3a, b ). For the same reason, the network of contacts, both van der Waals and hydrogen bonds, differed between the calculated and crystalized complexes (Figure 3c ), suggesting two different conformational states of the receptor. This finding corresponds to the published model of high-and low-affinity ternary complexes with the G protein, where for the low-affinity complex, GTP bound to the Gα subunit, the binding of G.H5 is shallow, and upon release of GDP, the stable, closed active conformation of the GPCR is formed. We also observed a bend at the end of TM6 in the simulations, indicating the beginning of the conformational change in the receptor; however, the timeframe of the MD simulations (200 ns for production runs) did not allow us to observe the full transition into the active state. Interestingly, in the simulations with the active conformation of the receptor, we did not observe the G-peptide binding the receptor despite similar starting positions of the G-peptide ( Supplementary Figures 5 and 6 ). The G-peptide would not enter the binding pocket even if pushed further into the binding cleft, resulting in interactions with ICL3 in the best-case scenario (Figure 3d , 3e; see an example in Supplementary Figure 6 ).
Discussion
In vitro results. Our experiments show that the allosteric effect from a G protein to the agonist binding pocket, postulated by DeVree and Sunahara, 8 can be mimicked by a synthetic peptide derived from the C-terminus of Gαi and detected in relatively simple competition binding experiments.
The saturation experiments performed with a radioligand and varying concentrations of the G-peptide showed the peptide affecting the binding in concentrations as low as 10 μM (Supplementary Figure 1) ; however, the experiments with morphine indicate that the characteristic shift in the binding curve associated with allosteric modulation cannot be observed when G-peptide concentrations are below 100 μM. This concentration corresponds to values reported for the rhodopsin study by Hamm et al. (100 -700 μM range) but is significantly higher than the concentrations of nanobodies reported in the literature (5 μM). The reason for this discrepancy can be the promiscuity of the peptide -sharing the sequence with Gα i , it can potentially cross interact with approximately 200 other GPCRs coupled to G i , thus decreasing the bioavailability of the peptide.
In our opinion, µOR was the key element of the experiments. The variety of wellknown ligands, the availability of functionally selective tool compounds and a number of crystal structures deposited in the PDB enabled the conduct and analysis of the experiments, both in vitro and in silico. In fact, it would be hardly possible to find another suitable target for such proof of concept. Computational study.
Our approach to the computational study differs significantly from those published previously. [29] [30] [31] Here, at the starting point of the MD simulations, the G-peptide was placed outside of the intracellular binding cleft in close proximity to the receptor (Supplementary Figure 5 ). This approach allowed us to observe unbiased binding of the peptide to µOR, as no peptide-receptor interactions were defined in the starting point of the simulation. Such a simulation system resulted in G-peptide drifting away from the receptor and failing to bind to the agonist-µOR complex. We have, however, introduced a bias on the secondary structure of the G-peptide, defining it on the basis of the C-terminus of the Gα s co-crystallized with β 2 -AR. 19 The native C-terminus of G proteins remains unstructured when not bound to a GPCR 32 , and our simulations on the G-peptide in water showed the instability of its secondary structure, oscillating between helical and unstructured ( Supplementary Figure 4) . Using the unstructured G-peptide as a starting point would significantly increase the simulation time, and the aim of the MD simulations run here was to detect the binding event of the G-peptide to the µOR. On the other hand, the helical structure of the peptide remained stable throughout the simulations of the ternary complex.
Binding of the G-peptide to the receptor, as revealed by the MD simulations, starts with forming a hydrogen bond between R 3x50 and D G.H5. 22 , followed by the formation of a hydrogen bond with ICL2 (R 34x57 ), stabilizing the orientation of the G-peptide within the binding cleft. This observation follows the findings of Elgeti et al., 30 which proposed a similar binding mechanism for rhodopsin and transducin CT-peptide. There, R 3x50 served as the anchor point for the peptide, leading, through mutual conformational adjustments, to stabilization of the helical structures of both the peptide and ICL3 and thus formation of the stable active conformation of rhodopsin. Those conclusions were drawn from NMR studies accompanied by MD simulations of crystal structures of rhodopsin (inactive, active and active with G t peptide), while in our experiments, we observed the same sequence of events starting from receptor and G-peptide separation.
The final G-peptide conformation obtained from MD simulations differs from the conformation of the corresponding region of Gα i from the crystal structure (PDB code: 6DDE) as well as from the conformation of transducin peptide crystallized with rhodopsin (PDB code: 3PQR). The angle at which the G-peptide remains in the binding site is similar to that in both crystal structures; however, it is rotated by approximately 90°. In addition, the Gpeptide does not enter as deep into the intracellular side of the receptor as can be observed in the crystal structures. The reason for this result is the depth of the binding site of the inactivestate µOR used in the calculations. Through the course of the MD simulations, we were not able to recreate the full transition to the active conformation of µOR, as the time scale of that rearrangement is significantly larger than that of the simulations performed. The different depth of binding of the G-peptide indicates differences in the interaction network between peptide and receptor ( Figure 3 ). Hydrogen bonds with TM6 (R 6x32 -L G.H5.25 ) are missing from the simulation results; TM3 also interacts through A 3x53 -N G.H5. 19 , and the hydrogen bond between R 3x50 and D G.H5.22 is absent in the crystal structures. The presence of key anchor hydrogen bonds with R 3x50 but a lack of hallmarks of GPCR activation (rotation of TM6 as well as wide opening of the intracellular crevice) indicate that the G-peptide-receptor conformation we obtained from MD simulations corresponds to the "low-affinity state" described by DeVree et al. or the early engagement complex described by Elgeti et al.
An interesting observation comes from the simulations performed with the active-state µOR (PDB code: 5C1M) as a starting point. In all of the MD runs we performed, the Gpeptide failed to enter the binding site of the receptor and was repelled by the interaction with D 8x47 from the hinge region between TM7 and H8 of the receptor. This result indicates that the G-peptide-receptor early engagement complex, or "low-affinity state", is essential for transition into the fully active state of the GPCR. The G protein (or G-peptide in this case) does not find an active-state receptor that it can stabilize. It engages the agonist-bound GPCR and pushes it into an activated "high-affinity state", which it then stabilizes. These findings provide evidence for the reaction mechanism driving GPCR activation described by Elgeti et al. but also add constraints to it, showing that formation of the early engagement complex with a characteristic hydrogen bond between the G-peptide and R3x50 for µOR is the first and essential step in the process of receptor activation.
Conclusions
Our results demonstrate that experiments with rhodopsin and the C-terminal peptide of a G protein performed nearly 30 years ago can be extrapolated to µOR. Moreover, our hypothesis of the length of ICL3 being the caveat of this approach can explain the lack of literature reports for the targets of interest of the GPCR research community. There is an overrepresentation of receptors with an extended ICL3 among GPCRs, but our findings open nearly 200 other receptors for further investigation of activation and biased signalling using synthetic peptides. Indeed, we show that by using the G-peptide, it is possible to differentiate between functionally selective compounds without a need for either cell-based assays detecting secondary messengers or receptor-tailored antibodies. 33 The computational study performed here corresponds to the model of rhodopsin activation, proposing a cooperative process of the receptor conformational rearrangement, indicating that it can indeed be universal for the GPCR superfamily. This study also conforms to the low-and high-affinity state model, showing that the initial low-affinity G-peptide-receptor ensemble is essential for the transition into a high-affinity ternary complex. 
Methods

Sequence analysis
The G protein binding data were extracted from GPCRdb. 1 The GPCRdb-annotated sequence segments were also extracted with an in-house script.
Molecular dynamics simulations
The structure of mouse µOR pre-aligned to a membrane was retrieved from the OPM database (entries 4DKL for inactive and 5C1M for active receptor conformations). The structure was then prepared with Schrödinger's Protein Preparation Wizard (bond orders, charges and OPLS3 force field parameters). Missing side chains as well as missing residues of ICL3 (residue numbers 264-269) were rebuilt with Prime. 2 The morphine structure was prepared using LigPrep 3 and docked into the prepared receptor (Schrödinger Glide XP, default settings). 4 A homology model of the G-peptide was prepared to retain the helical conformation. The peptide of 12 residues was built on the template 3SN6 (chain A) and prepared with Protein Preparation Wizard (charges and OPLS3 force field parameters as well as terminal acyl and amide groups). The crystal structure of the β 2 -adrenergic receptor bound to G s was the only available structure with a fully folded G.H5 of a G protein. The best crystal structure of Gα i , 1BOF, has the C-terminus partially unfolded and thus is unsuitable for the experiments. Two variants of the peptide were tested: wild type with 354F (G.H5.26) as the C-terminus and a reversed version, with 354F as the N-terminus. We did not observe any interactions between cap-protecting groups and the receptor in the MD simulations, and both variants of the peptide behaved in a similar manner. Models were created in Schrödinger's Maestro, using Prime backend (homology modelling) along with Protein Preparation Wizard (acylation and amidation).
The simulation system consisted of the receptor, the peptide and a POPC membrane. Clions were added to neutralize the system. The total atom count of the simulation system was approximately 47 000. The G-peptide was manually placed in close proximity to the intracellular binding cleft of the receptor. We ran several test simulations with the peptide placed further from the receptor to observe if spontaneous binding would occur. We observed spontaneous binding; however, this approach was not optimal for investigation of the µOR-G-peptide complex, and for these runs, the starting point for the simulations was with the two molecules close to each other. For these runs, which were repeated five times, we could observe the binding of the G-peptide in 4 out of 5 experiments with an inactive conformation of µOR. The starting conformation is visualized in Extended Data Figure 3 . Relaxation of the MD systems followed Schrödinger's relaxation protocol for membrane proteins. Production runs were performed at 310 K using the NPAT ensemble. The simulation time was 200 ns per simulation. Schrödinger software and in-house scripts utilizing Schrödinger python libraries were used for analysis of the trajectories. The last frame of a representative MD run was used to construct the interactions plot in Figure 3c . The plot was generated with Circos. 5 Structure figures were prepared with Schrödinger's Maestro 2018-1.
Peptide synthesis
All reagents, amino acids and solvents were purchased from commercial suppliers and used without further purification. The G-peptide was synthesized manually by a standard method, 9- 
Radioligand-binding assay
Crude membrane preparations isolated from Wistar rat brains were incubated at 25°C for 60 min with 0.5 nM [ 3 H]DAMGO in a total volume of 1 ml of 50 mM Tris-HCl (pH 7.4) containing bovine serum albumin (BSA) (1 mg/ml), bacitracin (50 mg/ml), bestatin (30 mM) and captopril (10 mM). All reactions were carried out in duplicate at a 10 mM peptide concentration. Incubations were terminated by rapid filtration through GF/B Whatman glass fibre strips using a Brandel 24 Sample Semi-Auto Harvester. The filters were washed with 2 ml of an ice-cold saline solution, and the bound radioactivity was measured in a MicroBeta LS, TriLux liquid scintillation counter (PerkinElmer). Nonspecific binding was determined in the presence of naltrexone hydrochloride (10 mM). The data were analysed by a nonlinear least square regression analysis computer program GraphPad Prism. We have investigated the effect of the G-peptide on [ 3 H]DAMGO binding to provide evidence on the allosteric cooperativity between the two. We conducted two types of experiments: competition binding against [ 3 H]DAMGO and saturation binding of the radioligand. The competition experiment allowed for determination of the IC 50 of the Gpeptide for the high and low range of concentrations, with values of 27.3 and 11.55 µM, respectively (see Supplementary Figure 1 for details). These values, compared to the nanomolar activity of DAMGO, render the G-peptide inactive through the orthosteric binding site of µOR. On the other hand, the saturation experiment revealed a concentration-dependent decrease in the B max value of DAMGO upon adding different concentrations of the G-peptide (two sets of experiments with G-peptide concentration ranging from 0.01-25 µM and 0.01-200 µM, see Supplementary Figure 2 ). These results indicate the allosteric coupling between DAMGO and the G-peptide and strengthen the interpretation of the binding curve shifts presented in Figure 2 as the allosteric effects.
Figure 1 | The distribution of the length of ICL3 in GPCRs. a,
The ICL3 among the GPCRs with known G protein coupling (GPCRdb and IUPHAR GuideToPharmacology data) tends to be short (shorter than 10 amino acids) for the majority of the analysed targets. This regularity is not maintained for G s -coupled receptors, with receptor ICL3s spanning all lengths. In the overall pool of GPCRs, the short loops are dominant (ca. 75% of receptors have an ICL3 of ten residues or shorter), whereas the crystallized targets have an overrepresentation of long ICL3s, which might affect the potential binding of a G-peptide. The lengths of ICL3s were calculated based on GPCRdb annotation of the receptor regions. b, An analysis of the active-state structures of GPCRs indicates the overrepresentation of the long-ICL3 receptors among the crystalized targets. In addition, rhodopsin, for which the first active-state structure was solved, is also the only target that has been crystalized without an antibody stabilizing the active conformation of the 7TM bundle. 
Figure 3 | Analysis of the modelled µOR-G-peptide complex. a,
The representative µOR-G-peptide complex obtained through MD simulations (pink ribbon, purple cartoon) overlapped with the crystal structures of metarhodopsin II crystalized with the C-terminal peptide of transducin (green cartoon, rhodopsin structure not shown for clarity, PDB code: 3PQR) and the µOR-G i complex (white ribbons for the receptor and orange for Cterminal part of G i , PDB code: 6DDE), showing a similar angle of the complexed G-peptide. b, The difference in depth of binding between G i and the G-peptide corresponds to the difference in the depth of intracellular binding sites of the active and inactive conformations of µOR. c, Comparison of the interaction network between G i and µOR and the G-peptide and µOR. The bands in the inner circle indicate the contacts that are unique to the crystal structure (white), unique to the calculated complex (grey), or common (black). The main difference in specific interactions detected is the presence of hydrogen bonds between D G.H5. 22 and R 3x50 , as found in the MD simulations (yellow ribbons), that are not present in the crystal structure (orange ribbons, shared hydrogen bonds are depicted with yellow ribbons with orange stroke). The change in the van der Waals network of contacts (crystal structure -grey lines, MD -black lines) is a consequence of the shallow binding pocket of the inactivestate µOR used in the experiments, resulting in a reduced solvent-accessible surface area of the crevice. d,e, Comparison of side-chain conformations of D 8x47 in active-(µOR-NB39, PDB code: 5C1M -yellow ribbons and atoms; µOR-G i as in a, side-chain of D 8x47 , missing in the electron density, has been modelled) and inactive-state (blue ribbons and atoms, PDB code: 4DKL; modelled complex as in a) conformations of µOR. In the inactive structures, the residue is facing away from the binding site, allowing the G-peptide to enter the pocket, whereas active structures have D 8x47 facing towards the TM bundle, interacting with the G protein or a nanobody and stabilizing the complex but on the other hand preventing the G-peptide from entering the binding site in the simulations performed on the active receptor conformation.
